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ABSTRACT 
 
B6 and C3H mice develop opposite Lyme arthritis phenotypes in response to the 
same Borrelia burgdorferi infection, providing a unique opportunity to use unbiased 
genetic approaches to identify host genes modulating pathogenic responses. Previously, 
gene expression profiling in joint tissue revealed a robust type I IFN profile in C3H mice 
that was formally linked to arthritis severity through IFNAR1 mAb blockade and genetic 
ablation. Independently, forward genetics identified a QTL, termed Borrelia burgdorferi 
arthritis-associated locus 1 (Bbaa1), which regulates Lyme arthritis severity and includes 
the type I IFN gene cluster. Here, interval specific congenic lines on B6 and C3H 
backgrounds were generated to mechanistically analyze the role of Bbaa1 as a regulator 
of Lyme arthritis severity.  
B6 mice congenic for the C3H Bbaa1 allele (B6.C3-Bbaa1) developed more 
severe Lyme arthritis than parental B6, which was correctable by IFNAR1 mAb blockade. 
Bbaa1 also regulated the magnitude of interferon-stimulated gene expression in BMDMs. 
Extensive analysis on phagocytic uptake, bacterial sensing and trafficking pathways, and 
IFN-responsive states further established that genes within Bbaa1 intrinsically control the 
differential IFN response. B6.C3-Bbaa1 mice also developed more severe K/B×N serum 
transfer arthritis through dysregulated type I IFN, establishing shared pathological 
processes in models of Lyme and rheumatoid arthritis. 
Refined, interval specific recombinant congenic lines further highlighted the
 iv 
contribution of C3H type I IFN genes to Lyme arthritis. Specific mAb blockade identified 
IFN-β (and not IFN-α) as the proarthritogenic type I IFN in B6.C3-Bbaa1 mice, and IFN-
β was solely responsible for interferon-stimulated gene expression and feed-forward 
amplification in BMDMs. Reciprocal radiation chimeras between B6.C3-Bbaa1 and B6 
mice illuminated a critical “pass off” in joint tissue, where radiation-sensitive cells 
initiate arthritis (likely through internalization-dependent initiation of IFN-β) and 
radiation-resistant joint resident cells choreograph arthritis development through 
myostatin upregulation. Together, these findings suggest tantalizing new options for 
therapeutic intervention in Lyme arthritic patients: (1) blockade of IFN-β to only partially 
suppress the antiviral response, and (2) blockade of myostatin to correct dysregulated 
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 Lyme disease is a multistage, multisystem inflammatory disorder triggered by 
infection with a tick-borne bacteria belonging to the genus Borrelia (1, 2). Lyme disease 
is rampant in the United States, Europe, and Asia, specifically in regions amenable to the 
life cycle of the Ixodes sps tick vector (3). The three primary disease-causing species of 
Borrelia are B. burgdorferi, B. afzelii, and B. garnii, but B. bavariensis has also been 
identified in a small percentage of cases (4–6). Borrelia burgdorferi is the only species 
found in the United States and causes approximately 300,000 cases of Lyme disease each 
year, making this the most common vector-borne disease in the U.S. (7). Unfortunately, 
Lyme disease incidence is expected to increase internationally as Ixodes populations are 
rapidly expanding due to many man-made changes to the environment (8). Thus, Lyme 
disease is a major global public health concern with an urgent need for preventative 
measures.  
 Lyme disease begins with a localized dermal infection at the site of the tick bite. 
Infection with B. burgdorferi usually manifests as a painless bulls-eye rash called an 
erythema migrans (which is diagnostic of infection) accompanied by flu-like symptoms 
including fever, headache, and fatigue (2, 9). Weeks to months after infection, B. 
burgdorferi disseminates (possibly through the bloodstream, lymphatic system, or direct 
penetration of tissues (10)) to distal sites of the body, typically the joint synovial fluid, 
nervous system, or heart (2). Thus, patients with disseminated infection may experience 
intermittent attacks of arthritis, neuropathies, or carditis, the latter of which can be deadly 
(7, 9, 11, 12). Early administration of oral antibiotics, including doxycycline, amoxicillin, 
or cefuroxime azetil, usually promotes a full recovery, while more severe neurological 
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and cardiac forms of illness require intravenous treatment with ceftriaxone or penicillin 
and have a worse prognosis (7). A subset of patients experience post-treatment Lyme 
disease syndrome (PTLDS) with continued fatigue, pain, or joint and muscle aches after 
antibiotic therapy (7). Although the exact cause of PTLDS is unknown (with hypotheses 
of infection-induced autoimmunity (13), persistence of nonviable bacterial antigens (14) 
or drug-tolerant persister cells (15)), long-term antibiotic therapy is clearly not effective 
(7) and these patients are currently underserved. 
 
Lyme Arthritis 
Lyme arthritis is the most common late disease manifestation, affecting up to 60% 
of untreated patients and persisting in 10% of patients after antibiotic therapy (16, 17). 
Lyme arthritis is characterized by edema, synovial hyperplasia, and neutrophil 
infiltration, and usually develops asymmetrically in the knee joint, though multiple joints 
may be affected throughout the course of infection (16, 18). A spectrum of Lyme arthritis 
severity exists among patients, ranging from acute-episodic to chronic-persistent (16, 19), 
and has been broadly attributed to the genetic composition of the host (involving genes of 
the immune response) as well as the infecting B. burgdorferi isolate (involving genes 
aiding dissemination and immune evasion) (20).  
The mouse model of Lyme arthritis has provided invaluable insight into all 
aspects of the host-pathogen interplay, particularly with regard to the genetic contribution 
of the host. Mice are reservoir hosts for B. burgdorferi infection in the wild (21), and 
inbred laboratory strains display a reproducible spectrum of arthritis severity in their rear 
ankle joints, with clinical features similar to human Lyme arthritis (22). Thus, in addition 
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to the plethora of laboratory tools and reagents available for mouse studies, the inherent 
genetic differences among mice has allowed the impact of host genes on pathogenic 
responses to be systematically explored in a natural model of B. burgdorferi infection.  
Accordingly, Weis et al. initiated a forward genetics approach over twenty years 
ago whereby C3H mice (which develop severe Lyme arthritis) were bred with C57BL/6 
(B6) mice (which develop mild Lyme arthritis), and identified six quantitative trait loci 
(QTL) associated with Borrelia burgdorferi arthritis development, termed Bbaa1-6 (23, 
24). Further analysis of the Bbaa2 mouse congenic line led to the identification of Gusb 
as a novel arthritis susceptibility gene (25) and validated the utility of this rigorous and 
unbiased approach. Importantly, the Weis group also conducted an unbiased screen using 
microarray technology to identify gene expression differences in C3H and B6 joint tissue 
that promote arthritis development (26). This thesis shows that these two independent 
approaches have converged on the identification of a pathologic type I IFN response, 
which is further elaborated below. 
 
The Interferon Family 
Interferons (IFNs) are a major family of cytokines first identified for their ability 
to interfere with viral replication (27). IFNs are divided into three classes (type I, II, or 
III) based on the receptors in which they interact (IFNAR1/2, IFNGR1/2, or IFNLR1/IL-
10R2, respectively) (28, 29). Type I IFN is the largest class, consisting of IFN-α, β, ε, κ, 
ω, or ζ (aka limitin) proteins, and is further expanded by numerous IFN-α subtypes (13 in 
humans and 14 in mice, not including pseudogenes) (30–32). Type II IFN consists of a 
single IFN-γ protein (33), and type III IFN is represented by four IFN-λ subtypes (29). 
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Although the IFN classes (as well as members) have distinct upstream triggers, 
downstream IFN-stimulated gene (ISG) profiles, and may be cell type or tissue-restricted, 
each plays a vital role in immunomodulation—with balanced regulation being key to 
their antimicrobial success (29, 33–35).  
 
Pathologic Type I Interferon in Lyme Disease 
Soon after the protective role of IFNs was established, their dichotomous ability 
to promote pathogenesis became evident (28, 33, 36). In the case of Borrelia burgdorferi 
infection, IFN pathogenicity was first suspected when an unbiased microarray analysis 
identified a preclinical IFN profile in the joint tissue of Lyme arthritis susceptible C3H 
mice that was absent in Lyme arthritis resistant B6 mice (26). Although the ISGs 
identified by the microarray could have been induced by type I or II IFNs (26), IFN-γ had 
already been shown to be dispensable for Lyme arthritis development in C3H mice (37). 
Thus, the contribution of type I IFN was assessed by IFNAR1 mAb blockade (38) and 
genetic ablation (39) and revealed a significant (and equivalent) reduction in Lyme 
arthritis severity in C3H mice, formally linking pathologic production of type I IFN to 
arthritogenesis. Intriguingly, an independent forward genetics approach also revealed the 
type I IFN gene cluster in the Borrelia burgdorferi arthritis-associated locus 1 (Bbaa1), a 
QTL regulating arthritis severity (23, 24). Further analysis of Bbaa1 is the subject of 
Chapters 2 and 3. 
The surprising finding that B. burgdorferi, an extracellular pathogen, induces type 
I IFN production in mice has also been observed in humans (40, 41), and multiple studies 
have been conducted in both human and murine cells in order to better understand the 
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mechanism of B. burgdorferi-triggered IFN-induction. Specifically, B. burgdorferi 
factors capable of inducing a type I IFN profile include the surface lipoprotein OspA, 
various secreted non-nucleic acid ligands, RNA, linear plasmid 36, and other 
dissemination factors (42–46). Host pattern recognition receptors (PRRs) involved in 
IFN-induction in response to B. burgdorferi include NOD2 (47), TLR2 (48, 49), TLR8 
(in human monocytes) (43, 50), TLR7 and TLR9 (in human peripheral blood 
mononuclear cells (51) and dendritic cells (44)), and there seems to be a MyD88- and 
TRIF-independent pathway (52) but details remain to be elucidated. In regard to the 
initiating cell type, there is a unique requirement for phagocytosis and degradation of B. 
burgdorferi (38, 47, 49, 50). This was corroborated by the finding that CD45+ cells 
harvested from a naïve mouse joint are capable of generating an IFN profile upon B. 
burgdorferi stimulation, whereas CD45- cells are only capable of responding to 
exogenous IFN-β protein (39).  
Undoubtedly, IFN-induction in response to B. burgdorferi is complex, but the 
empirical identification of a differential type I IFN response between B6 and C3H mice 
(26, 38, 39) that was also suggested by forward genetics (23, 24) has provided a unique 
platform to uncover novel genetic mechanisms of type I IFN regulation.  
 
Pathologic Type I Interferon in Other Diseases 
There are additional links between arthritis and type I IFN in other diseases. 
Specifically, arthritis is a documented side effect of hepatitis C (53) and multiple 
sclerosis (54) patients treated with type I IFN. Arthritis is also a common symptom of 
systemic lupus erythematosus patients, who, for still unclear etiological reasons, 
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aberrantly produce type I IFN (55). And, a subset of rheumatoid arthritis patients, 
particularly those who fail to respond to TNF-α blockade, display an IFN signature (56) 
and will require novel treatment strategies (57).  
Moreover, a number of viral infections including human immunodeficiency virus 
(58), hepatitis C virus (59), and persistent lymphocytic choriomeningitis virus (60) 
induce a type I IFN profile that has been correlated with disease severity. Other bacteria 
that have been reported to use type I IFN to their advantage include Listeria 
monocytogenes, Francisella tularensis, and Mycobacterium tuberculosis (28). Other 
autoimmune diseases that have been associated with dysregulated type I IFN include 
Sjögren’s syndrome (61), scleroderma (62), type I diabetes (63), and systemic sclerosis 
(64). Thus, pathologic production of type I IFN is highly relevant to a plethora of human 
diseases, and insights gleaned from our model may transcend Lyme disease.  
 
Preview of Dissertation Research 
This dissertation focuses on examining the role of Bbaa1 (the QTL that harbors 
the type I IFN locus (23, 24)) in modulating Lyme arthritis severity. In Chapter 2, we 
developed Bbaa1 interval specific congenic lines on the B6 and C3H backgrounds and 
tested the hypothesis that type I IFN within Bbaa1 drives Lyme arthritis severity. In 
Chapter 3, we assessed the specific contributions of IFN-α and IFN-β to Lyme arthritis 
severity, refined the Bbaa1 congenic line, and utilized RNA-seq to elucidate the 
mechanism of Bbaa1-directed Lyme arthritis development. In addition to the novel 
findings presented herein, this work will provide the foundation for uncovering novel 
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DYSREGULATED PRODUCTION OF IFN-β BY BORRELIA BURGDORFERI 
ARTHRITIS-ASSOCIATED LOCUS 1 (BBAA1) DRIVES 










Forward genetics previously identified a genetic locus, denoted B. burgdorferi 
arthritis-associated locus 1 (Bbaa1), which regulates Lyme arthritis through heightened 
production of type I IFN and which physically encompasses the type I IFN gene cluster.  
In this study, mAb blockade of IFN-β, but not IFN-α, suppressed Lyme arthritis 
development in B6.C3-Bbaa1 mice. Bbaa1 regulation of IFN-β was also identified in 
bone marrow-derived macrophages stimulated with B. burgdorferi, and was responsible 
for feed-forward amplification of interferon-stimulated genes. Reciprocal radiation 
chimeras between B6.C3-Bbaa1 and B6 mice revealed that arthritis is initiated by 
radiation-sensitive cells, but orchestrated by radiation-resistant components of the joint 
tissue. Advanced congenic lines were developed in order to reduce the physical size of 
the Bbaa1 interval, and confirmed the contribution of type I IFN genes to Lyme arthritis.  
RNA-seq of the resident CD45- joint cellular fraction from advanced interval specific 
recombinant congenic lines (ISRCL4 and ISRCL3) identified myostatin as uniquely 
upregulated in association with Bbaa1 arthritis development, and demonstrated myostatin 
expression to be linked to IFN-β production. Furthermore, in vivo inhibition of myostatin 
suppressed Lyme arthritis in Bbaa1 (ISRCL4) congenic mice, formally implicating 
myostatin as a downstream mediator of joint-specific inflammatory response to B. 
burgdorferi. These findings suggest a previously unappreciated role for myostatin in 





Lyme disease, caused by infection with the bacteria Borrelia burgdorferi, affects 
300,000 Americans each year (1). Disease outcomes range from acute to chronic, 
sometimes resulting in irreversible damage to the nervous (2) and cardiovascular (3, 4) 
systems. Arthritis is the most common late disease manifestation (5), affecting up to 60% 
of patients and persisting in 10% of patients despite antibiotic therapy (6). Lyme arthritis 
is frequently characterized by synovitis at one or both knee joints and may persist for 
years after infection (6, 7). While both bacterial and host factors contribute to the 
spectrum of Lyme disease severity (8), many studies have shown that Lyme arthritis 
results from a genetically determined dysregulated immune response (9–17).  
The spectrum of disease severity in humans can be modeled in inbred strains of 
mice, which display different disease outcomes upon infection with B. burgdorferi (13). 
Specifically, C57BL/6 (B6) mice develop mild arthritis and C3H mice develop severe 
arthritis in response to the same B. burgdorferi inoculum. We have successfully 
employed these mice during empirical (18, 19) and forward genetic (20–22) approaches 
to identify genetic determinants of Lyme arthritis severity. Empirical approaches 
comparing the global gene expression profiles of B6 and C3H joint tissue revealed a type 
I IFN signature in C3H mice that is absent from B6 mice (18), and a receptor-blocking 
antibody and receptor ablation formally linked type I IFN expression to Lyme arthritis 
severity. Independently, forward genetic approaches identified a quantitative trait locus 
(named Bbaa1) that contains the type I IFN gene cluster and controls Lyme arthritis 
severity (20). An interval specific congenic line in which the C3H Bbaa1 allele was 
introgressed onto the B6 background (B6.C3-Bbaa1) displays increased Lyme arthritis 
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relative to B6 mice (20) unless pretreated with the type I IFN receptor-blocking antibody 
(21), formally linking the expression of type I IFN within Bbaa1 to increased Lyme 
arthritis. Interestingly, Bbaa1 was also found to regulate rheumatoid arthritis (RA) 
severity through type I IFN production (21), indicating that insight gleaned from our 
model extends to a distinct inflammatory arthritis. 
Our finding of a pathologic type I IFN profile is consistent with several 
publications that have shown a type I IFN signature in the serum of human Lyme patients 
at stages of active disease (2, 23) and in the synovial fluid of treatment-refractory RA 
patients (24). Arthritis is also a transient side effect in hepatitis C and multiple sclerosis 
patients treated with IFN-α/β (25, 26), further supporting the linkage between elevated 
levels of type I IFN and arthritis. However, type I IFN is a key element in the innate and 
adaptive response against a variety of microbial infections, posing an inherent problem to 
treatment blockade. Because type I IFN regulation requires a sensitive balance, and 
because IFN-α and IFN-β members play unique roles in various infections, we sought to 
identify the specific type I IFN driving Lyme arthritis pathogenesis. Our unique genetic 
tools have allowed us to separate type I IFN production from the IFN response (which is 
triggered immediately upon cytokine sensing), and to look at type I IFN production in 
isolation from other QTL contributing to Lyme arthritis severity (20). Herein, we used 
the B6.C3-Bbaa1 mouse to identify the specific type I IFN member that causes Bbaa1 
Lyme arthritis, segregated cells that initiate type I IFN in response to B. burgdorferi from 





Materials and Methods 
Mice 
B6 and C3H mice were obtained from Jackson Laboratories. B6.C3-Bbaa1 mice 
(Chr4: 9.32-94.97 Mbp) were previously generated (20) and maintained as a colony in 
our Animal Research Center. Interval specific recombinant congenic lines (ISRCL1-4) 
with Chr4 Bbaa1 intervals 11.6 – 77.8 Mbp, 76.48 – 93.46 Mbp, 83.7 – 93.46 Mbp, and 
88.3 – 93.46 Mbp were generated through repeated backcrosses of B6.C3-Bbaa1 to the 
parental B6 line. Filial offspring were selected based on SNP identification by high-
resolution melting analysis as described (27), and homozygous lines were fixed by 
mating littermates. All mice used in this study were housed in the University of Utah 
Animal Research Center (Salt Lake City, UT) and handled in accordance with protocols 
approved by the institutional review committee. 
 
B. burgdorferi cultures, infections, and arthritis assessments 
B. burgdorferi strain N40 was cultured for 4 days in Barbour-Stoenner-Kelly II 
medium containing 6% rabbit serum (Sigma-Aldrich). Mice were infected with 2×104 
live spirochetes intradermally into the skin of the back (28).  Arthritis was assessed by 
rear ankle joint measurements obtained with a metric caliper at days 0 and 28 post 
infection, and by histopathological analysis of the most severely swollen rear ankle joint 
following fixation, decalcification, and H&E staining as described previously (29). 
Histopathological scores were determined blindly and ranged from 0 to 5 for various 
aspects of disease, including severity and extent of the lesion, PMN leukocyte and 
mononuclear cell (e.g. monocyte, macrophage) infiltration, tendon sheath thickening (e.g. 
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synoviocyte and fibroblast hyperplasia), and reactive/reparative responses (e.g. periosteal 
hyperplasia and new bone formation and remodeling), with 5 representing the most 
severe lesion and 0 representing no lesion. Infection was confirmed in mice euthanized 
28 days post infection by ELISA quantification of B. burgdorferi specific IgG 
concentrations in serum (30) and 16S rRNA B. burgdorferi transcripts in joints (31).   
 
Inhibitory reagents and treatments 
Monoclonal Abs were used to neutralize murine IFNAR1 (MAR1-5A3), IFN-α 
(TIF-3C5), or IFN-β (HDβ-4A7) (Leinco Technologies, Inc.). TIF-3C5 is considered a 
“pan-IFN-α” mAb because it neutralized all IFN-α subtypes available for testing: αA, α1, 
α4, α5, α11, and α13 (32). Mice received mAbs or isotype controls by intraperitoneal 
injection following a dosage regimen described previously (32, 33). Briefly, anti-
IFNAR1 was administered in a single 2.5mg dose the day before infection with B. 
burgdorferi (19, 21, 33), anti-IFN-β was administered in two doses (300µg each, 600µg 
total) the day before and 2 days following infection, and anti-IFN-α was administered in 
three doses (333µg each, 1mg total) the day before and days 1 and 3 post infection. 
Boosts were determined based on pharmacokinetics previously reported (32) and in 
consideration with the IFN profile peak 7 days post infection with B. burgdorferi (18). 
For BMDM experiments, 10µg/ml of each mAb was administered in combination with 
the stimulation. The myostatin inhibitor (MBP-fMSTNpro45-100-Fc) is a recombinant 
peptide derived from the prodomain of full-length myostatin protein, as described (34). 
Mice received four intraperitoneal injections of vehicle (PBS) or myostatin inhibitor 
(400µg each, 1.6mg total) once weekly beginning the day after infection. 
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Generation of reciprocal radiation chimeras 
Chimeras were generated in all pairwise combinations between B6 (CD45.1), B6 
(CD45.2), and B6.C3-Bbaa1 (CD45.2) using a rapid reconstitution protocol as described 
(35, 36). Rapid reconstitution involves transplanting donor splenocytes into irradiated 
recipient mice and allows for the infection of young mice <8 wk old, necessary for a 
reliable arthritis phenotype. Chimerism was evaluated by flow cytometric analysis of 
peripheral blood leukocytes 25 days post transplant (Figure 3.S3A).  
 
Isolation of CD45- cells from joint tissue 
Mouse rear ankle joints were gently digested into single-cell suspensions as 
described (36). Briefly, skin was removed and tibiotarsel tissue was teased away from 
bone using 20-gauge syringe needles followed by 1 hr incubation at 37oC in RPMI 1640 
containing 0.2mg/ml endotoxin-free Liberase TM (Roche) and 100µg/ml DNase I 
(Sigma-Aldrich). Single-cell suspensions were filtered through a 100µm cell strainer, 
RBCs were lysed in ammonium-chloride-potassium buffer, and cells were labeled with 
biotinylated anti-CD45.2 (BioLegend) followed by streptavidin magnetic bead labeling 
(Miltenyi Biotec). Magnetic bead separation was performed on MS columns (Miltenyi 
Biotec) according to the manufacturer’s instructions. Flow cytometric analysis revealed 
>85% purity in the CD45- fraction, as previously reported (36). CD45- cells from both 
rear ankle joints of two mice were pooled for each n sample in order to increase RNA 
concentration for transcript analysis (Figures 3.6 and 3.7A). For ex vivo stimulation, 
CD45- cells from both rear ankle joints of >8 mice were pooled, plated in RPMI 1640 
containing 2% FBS (36), and stimulated with live B. burgdorferi (6×106/ml) or 100U/ml 
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IFN-β (PBL Laboratories) for 3 hr (Figure 3.7B). 
 
Cell culture 
Bone marrow-derived macrophages (BMDMs) were prepared by culturing bone 
marrow isolated from the femurs and tibias of mice for 7 days in L929 cell-conditioned 
media as a source of M-CSF, as previously described (37). Harvested macrophages were 
then replated in 24-well dishes at a density of 6×105/ml in media containing 1% of the 
serum replacement Nutridoma (Roche). Cultures were stimulated with live B. burgdorferi 
(6×106/ml) for 6hr at 37oC with 5% CO2.  
 
Flow cytometric analysis of P-Stat 1 
Phosphorylated Stat1 was stained as described (32, 38) following 15hr incubation 
with B. burgdorferi and type I IFN blocking mAbs. Briefly, cells were incubated in 
0.05% trypsin (Fisher Scientific) and scraped to detach from plate. Cells were fixed using 
1.5% paraformaldehyde and permeabilized with 100% methanol. P-Stat1 was stained 
using an unconjugated Phospho-Stat1 mAb (pY701, Cell Signaling) at a 1:200 dilution 
and incubated for 1 hr at RT, followed by a secondary stain with Goat anti-Rabbit IgG 
conjugated to Alexa Fluor 647 (Fisher Scientific) at a 1:500 dilution and incubated for 30 
min at RT. Data were collected on a FACSCanto II (BD Biosciences) flow cytometer and 





Gene expression analysis 
Total RNA was recovered using TRIzol reagent (Invitrogen) and purified using 
the Direct-zol RNA MiniPrep kit (Zymo Research). For RNA-sequencing, libraries were 
prepared using PolyA enrichment and sequenced with Illumina HiSeq 50 Cycle Single-
Read Sequencing version 4 at the University of Utah High Throughput Genomics Core 
Facility (Salt Lake City, UT). Sequences were aligned and annotated with help from the 
University of Utah Bioinformatics Core Facility (Salt Lake City, UT). For qRT-PCR 
analyses, RNA was reverse transcribed, and transcripts were quantified using a Roche 
LC-480 according to our previously described protocols (20). Primer sequences used in 
this study for β-actin, Iigp (18), Oasl2, Cxcl10, Tyki (19), Gbp2 (39), Tnfa, and Ifnb (40) 
can be found at the indicated citations. Mstn primer sequences designed in this study 
were as follows: forward (5’-GATCTTGCTGTAACCTTCCC-3’) and reverse (5’-
CTCCTGAGCAGTAATTGGC-3’). 
 
Data and statistical analyses 
All graphical data depict the mean + SEM. Statistical analyses were performed 
using GraphPad Prism 7.0b software. Multiple-sample data sets were analyzed by one-
way ANOVA with Dunnet’s post hoc test for pairwise comparisons. Two-sample data 
sets were analyzed by Student t test (2-tailed). Categorical histopathology scores were 
assessed by the Mann-Whitney U test. Statistical significance (*p < 0.05, **p < 0.01, 






Determination of the proarthritogenic type I IFN cytokine in  
B6.C3-Bbaa1 mice 
Both empirical and forward genetic studies from our lab have converged on the 
finding that a pathologic type I IFN profile drives Lyme arthritis in C3H mice (18–21, 
36). We identified the type I IFN gene cluster in Bbaa1, a QTL regulating Lyme arthritis 
severity, and generated a congenic line, denoted B6.C3-Bbaa1 (Chr4: 9.32-94.97 Mbp), 
wherein we established that dysregulated production of type I IFN within Bbaa1 drives 
Lyme arthritis (21). Nevertheless, there are multiple members of the type I IFN family, 
with the IFN-α subtypes and IFN-β playing the largest roles in pathogenesis to date, and 
although each signals through a shared receptor heterodimer, their unique roles in host 
protection and pathogenesis are becoming increasingly appreciated (32, 41).  
To assess the specific contribution of IFN-α and IFN-β to Lyme arthritis 
development, B6.C3-Bbaa1 mice were treated with a pan-acting mAb that blocks 
multiple IFN-α subtypes (TIF-3C5) or a mAb that targets IFN-β specifically (HDβ-4A7). 
We previously showed that the anti-IFNAR1 mAb (MAR1-5A3) suppresses arthritis 
development to the baseline of B6 (21). Because blocking IFN-β resulted in the same 
reduction in Lyme arthritis as blocking IFNAR1 (Figure 3.1A), we conclude that IFN-β 
and not IFN-α is the proarthritic cytokine generated in B6.C3-Bbaa1 mice. Analysis of 
anti- B. burgdorferi IgG in the serum and B. burgdorferi 16S rRNA transcripts in the joint 
confirm that blocking type I IFN does not impact the ability of the host to generate a B-
cell response or to control infection (Figure 3.1B). These findings underscore the fact that 
Bbaa1 intrinsically regulates pathologic production of IFN-β in vivo, and IFN-β does not 
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protect the host from B. burgdorferi expansion.  
 
Effect of blocking IFN-α or IFN-β on type I IFN activation in BMDMs 
We previously showed that BMDMs from B6.C3-Bbaa1 mice express higher 
levels of IFN-inducible transcripts in response to B. burgdorferi than do BMDMs from 
B6 mice (21). Thus, B6.C3-Bbaa1 BMDMs were used as a surrogate for myeloid cells in 
joint tissue to assess the specific contribution IFN-α or IFN-β to the Bbaa1-directed 
induction of type I IFN. BMDMs were stimulated with B. burgdorferi and treated with 
each mAb for 6 hr. Treatment with anti-IFN-β resulted in complete suppression of IFN 
inducible genes, indistinguishable from levels of macrophages treated with IFN receptor 
blockade (Figure 3.2A). In contrast, treatment with anti-IFN-α had no effect on IFN-
induction, indicating that IFN-β, and not IFN-α, is regulated by Bbaa1 in response to B. 
burgdorferi. Isotype control mAbs had no effect (Figure 3.S1). Importantly, none of these 
treatments impacted the expression of Tnfa (Figure 3.2A), which is downstream of the 
critical MyD88-dependent host defense pathway (42, 43). This highlights the in vivo 
observation that type I IFN is not required for host defense in Lyme arthritis (Figure 
3.1B) and its suppression does not influence the expression of initial MyD88-dependent 
cytokines (21, 36)  
Flow cytometric analysis of phosphorylated Stat1 protein was used as a 
complementary approach to determine the impact of IFN-α and IFN-β protein on the 
feed-forward IFN amplification. Stat1 is rapidly phosphorylated when IFN-α and IFN-β 
proteins bind the receptor (32, 44), but stimulation with B. burgdorferi requires time for 
transcription and translation of type I IFNs. Therefore, Stat1 phosphorylation was 
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assessed in BMDMs 15 hr post stimulation with B. burgdorferi and mAb treatment. 
Strikingly, IFN-β neutralization completely inhibited Stat1 phosphorylation, similar to 
levels in macrophages treated with receptor blocking mAb, while blocking IFN-α had no 
effect (Figure 3.2B). Because anti-IFN-α did not impact arthritis severity or macrophage 
responses to B. burgdorferi, mAb functionality was assessed (Figure 3.S2). Confirmation 
of anti-IFN-α activity supports the conclusion that IFN-β (but not IFN-α) is the type I 
IFN made in response to B. burgdorferi both in vivo and in vitro, and that low levels of 
IFN-α do not contribute to response during the feed-forward amplification. 
 
Does Bbaa1 initiate arthritis through hematopoietic or resident cells? 
Multiple lines of evidence point to the fact that IFN-β is pathologic in Bbaa1 
congenic mice, leading to the question of whether Bbaa1 exerts its proarthritic effect 
through hematopoietic or resident cells. The Bbaa1 congenic mouse is a unique tool that 
allows the interrogation of IFN signaling independent of feed-forward IFN amplification 
because Bbaa1 initiates IFN-β production. MHC compatibility between mildly arthritic 
B6 mice and more severely arthritic B6.C3-Bbaa1 mice allowed reciprocal radiation 
chimeras to be generated to specifically determine if Bbaa1 exerts its proarthritic effect 
through radiosensitive-hematopoietic cells or radioresistant-resident cells in the joint 
(Figure 3.3A). Chimeras were generated using a rapid reconstitution protocol (35, 36), 
and reconstitution was determined to be adequate for host defense based on the similar 
abilities of irradiated mice to generate a B-cell dependent antibody response and 
sufficient myeloid cells to control infection (Figure 3.S3).  
As expected, B6 mice reconstituted with autologous splenocytes (B6→B6) 
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developed mild arthritis and B6.C3-Bbaa1 mice reconstituted with autologous 
splenocytes (Bbaa1→Bbaa1) developed more severe arthritis 4 wk post infection with B. 
burgdorferi (Figure 3.3B). Notably, B6.C3-Bbaa1 mice reconstituted with B6 cells 
(B6→Bbaa1) developed mild arthritis similar to B6→B6 chimeras, whereas B6 mice 
reconstituted with B6.C3-Bbaa1 cells (Bbaa1→B6) developed severe arthritis 
indistinguishable from Bbaa1→Bbaa1 chimeras (Figure 3.3B). Thus, Bbaa1 regulates 
Lyme arthritis severity through the radiosensitive, hematopoietic cellular constituents of 
the joint. Considering that Bbaa1 controls the magnitude of B. burgdorferi-triggered IFN-
β production, we can further deduce that radiosensitive cells in the joint, which are likely 
myeloid (36), initiate the production of proarthritic IFN-β (Figure 3.3C). This is 
consistent with our previous findings that CD45+ cells harvested from a naïve mouse 
joint possess the unique ability to generate an IFN profile upon ex vivo stimulation with 
B. burgdorferi, whereas CD45- cells are capable of responding to but not initiating type I 
IFN in response to B. burgdorferi (Figure 3.S4 and Lochhead et al. (36)). Another 
striking finding is that Bbaa1→B6 chimeras develop the full arthritis phenotype, strongly 
implicating that regardless of genotype, radioresistant-resident cells are fully competent 
to choreograph arthritis manifestation in the joint (Figure 3.3, B and C). This is consistent 
with the previous finding that endothelial cells and fibroblasts, both of which are 
radioresistant cell types in the joint, are major responders to and amplifiers of type I IFN 
resulting in production of chemokines in infected C3H mice (36). This provides the first 
in vivo evidence for the “pass off” that occurs between cells that initiate IFN-β in 
response to B. burgdorferi and cells that respond to IFN-β to direct arthritis development 
(Figure 3.3C).  
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C3H-derived Bbaa1 genes spanning the type I IFN locus confer  
increased arthritis on B6 background 
Because the original B6.C3-Bbaa1 congenic interval was very large (Chr4: 9.32 – 
94.97 Mbp) with >450 genes in addition to Ifnb, it was necessary to reduce the physical 
interval by backcrossing B6.C3-Bbaa1 to the parental B6 line. This led to the generation 
of four new Bbaa1 interval specific recombinant congenic lines (denoted ISRCL1-4) 
harboring various subintervals of Bbaa1 (Figure 3.3). ISRCL1 contains the largest 
portion of C3H Chr4 but excludes the C3H type I IFN locus, while ISRCL2-4 retains the 
C3H type I IFN gene cluster with further reduction in the amount of C3H donor sequence 
(Figure 3.4). After infection with B. burgdorferi, congenic lines retaining C3H-derived 
Bbaa1 genes spanning the type I IFN locus displayed more severe arthritis compared to 
B6 mice (Figure 3.4). Importantly, ISRCL3 mice exhibit the same arthritis phenotype as 
B6.C3-Bbaa1 mice, indicating that all of the genes required for maximal Bbaa1 arthritis 
are contained within Chr4: 83.7 – 93.46 Mbp. Interestingly, ISRCL4 mice displayed a 
submaximal phenotype that was still significantly increased compared to B6 mice. This 
indicates that there are 2 loci regulating maximal Bbaa1 arthritis: the first locus is shared 
by ISRCL3 and ISRCL4 mice and spans the type I IFN gene cluster, while the second 
locus is only contained in ISRCL3 mice and is outside of type I IFN genes. Nevertheless, 
because blocking IFN-β in the full-length B6.C3-Bbaa1 congenic line completely 
suppresses Lyme arthritis (Figure 3.1A and Ma et al. (21)), we can infer that the 
phenotype of both of these loci is dependent on IFN-β production.  
Next we assessed the magnitude of the IFN response to B. burgdorferi in BMDMs 
from ISRCL3 and ISRCL4 mice, which both possess the C3H allele for the type I IFN 
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locus. Importantly, BMDMs from ISRCL3 and ISRCL4 mice displayed greater IFN 
transcriptional responses than BMDMs from B6 mice, with magnitudes similar to full 
length B6.C3-Bbaa1 BMDMs (Figure 3.5). This indicates that genes responsible for IFN-
β dysregulation are retained in the ISRCL4 Bbaa1 locus (Chr4: 88.3 – 93.46 Mbp). As 
shown, Ifnb expression is low, but none of the 14 IFN-α transcripts were detectable, 
further supporting the role of IFN-β in driving Lyme arthritis pathogenesis. The fact that 
ISRCL3 & ISRCL4 mice display greater arthritis severity and their macrophages express 
more Ifnb compared to B6 macrophages provides a refined tool to study Bbaa1 Lyme 
arthritis.  
 
How does Bbaa1 change the transcriptome of the  
radioresistant-resident responders? 
Now that we have established the role of radioresistant-resident cells in directing 
Bbaa1 Lyme arthritis downstream of IFN-β, we pursued a better understanding of the 
mechanism of arthritis development through transcriptome analysis of CD45- (resident) 
joint cells. Newly developed ISRCL3 and ISRCL4 lines were compared to B6 mice in 
order to capture all genes related to IFN-β production and arthritis development with a 
minimal physical interval. To capture the stage of active arthritis development (as 
opposed to full-blown arthritis with confounding wound repair pathways), joint cells 
were harvested from mice 22 days post infection with B. burgdorferi. Following recovery 
of single-cell suspensions, the CD45- population was isolated by magnetic bead 
separation and RNA-seq was performed.  
Not surprisingly, comparing the transcriptomes of these highly similar genotypes 
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at a time point submaximal to arthritis development revealed very few differences in gene 
expression profiles (Figure 3.6A). Of those differences, only five genes were 
independently identified in both ISRCL4 vs. B6 and ISRCL3 vs. B6 comparisons with 
>1.5-fold change and p-adj <0.05 (Figure 3.6A & Figure 3.S5), supporting their 
involvement in Bbaa1-directed arthritis. Importantly, myostatin (Mstn) had the greatest 
induction and achieved the highest level of significance in both analyses (Figure 3.6A & 
Figure 3.S5), illuminating it as a strong candidate for Bbaa1 Lyme arthritis development. 
Quantitative RT-PCR analysis of Mstn expression in CD45- cells from uninfected animals 
revealed similar expression among uninfected mice of all three genotypes (data not 
shown), and revealed that Bbaa1 specifically regulates the induction of myostatin 
following infection with B. burgdorferi (Figure 3.6B). This was a striking finding for 
Bbaa1 Lyme arthritis development in light of recent evidence that myostatin is involved 
in RA development in humans and mice (45).  
 
Impact of IFN-β on myostatin expression in CD45- cells isolated  
from joint tissue 
To assess the connection between IFN-β production and myostatin expression in 
Bbaa1 Lyme arthritis, IFN-β was blocked in ISRCL4 and ISRCL3 mice infected with B. 
burgdorferi (as described in Figure 3.1). CD45- cells were isolated from joint tissue 22 
days post infection, and myostatin expression was assessed by qRT-PCR. Importantly, 
CD45- cells from ISRCL4 and ISRCL3 mice infected with B. burgdorferi and treated 
with anti-IFN-β mAb expressed nearly 2-fold fewer Mstn transcripts compared to mice 
treated with isotype control (Figure 3.7A). The fold suppression by blocking IFN-β is 
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internally consistent with the level of induction found in our RNA-seq (Figure 3.6). This 
directly connects the Bbaa1-dependent production of IFN-β to Mstn upregulation in vivo.  
Several proinflammatory cytokines, TNF-α, IL-1α, and IL-17, were previously 
shown to directly induce expression of myostatin in the context of RA, but the impact of 
IFN-β was not addressed (45). To test whether IFN-β directly induces expression of 
myostatin, CD45- cells were isolated from the joints of naïve B6 mice and stimulated ex 
vivo with IFN-β, B. burgdorferi, or IFN-β and B. burgdorferi in combination. Mstn 
expression assessed by qRT-PCR revealed that IFN-β works synergistically with B. 
burgdorferi to directly induce Mstn expression (Figure 3.7B). To our knowledge, this is 
the first report of IFN-β induction of myostatin.  
 
Inhibition of myostatin suppresses Lyme arthritis in Bbaa1  
congenic mice  
In order to determine whether myostatin is a marker or a mediator of Bbaa1 Lyme 
arthritis, infected ISRCL4 mice were treated with a highly effective myostatin propeptide 
(34) to inhibit myostatin protein activity during arthritis development. Consistent with the 
dual requirement of B. burgdorferi and IFN-β for myostatin upregulation (Figure 3.7, A 
and B), myostatin inhibition did not impact ankle swelling in uninfected animals (Figure 
3.8). However, myostatin inhibition in infected ISRCL4 congenic mice led to a 
remarkable suppression in arthritis 4 wk post infection with B. burgdorferi (Figure 3.8), 
similar to the low level normally seen in infected B6 mice (Figure 3.4). These findings 





In this study, we established IFN-β as the Lyme arthritis-driving type I IFN that is 
regulated by a locus, Bbaa1, previously identified by forward genetics. This culminates a 
decade of our work wherein two parallel pathways of investigation revealed a pathologic 
type I IFN profile in C3H mice infected with B. burgdorferi that is suppressed by 
IFNAR1 blockade (14, 18–21, 36). Others have corroborated the association between 
pathologic production of type I IFN and Lyme disease pathogenesis in murine studies 
(46, 47)  as well as in human patients at various stages of disease (2, 23), and many 
investigators have examined the type I IFN response to B. burgdorferi in murine and 
human cells (19, 36, 39, 47–56). But the specific culprit of B. burgdorferi-induced type I 
IFN pathogenicity has remained elusive due to the transient expression of IFN-α/β (57, 
58), overlapping interferon-stimulated gene pathways induced by IFN-α/β (59), and 
differing contexts of B. burgdorferi infection in which IFN-α/β transcripts have been 
detected. The strength of this study centers on the employment of B6.C3-Bbaa1 mice, 
which allowed the impact of type I IFN dysregulation to be assessed in isolation from the 
five other B. burgdorferi arthritis-associated QTL contained within the C3H genome 
(20), coupled with the use of newly available mAbs to assess IFN-α and IFN-β 
individually.  
Multiple mAb experiments along with the transcriptional detection of Ifnb in 
BMDMs from refined congenic lines (and lack of evidence for Ifna transcripts) revealed 
that IFN-β is the sole contributor to the type I IFN profile and arthritogenesis in Bbaa1-
directed Lyme arthritis. Another major finding was that IFN-β is intrinsically controlled 
within the Bbaa1 locus. The intrinsic regulation of IFN-β within Bbaa1 was surprising 
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due to the lack of coding or regulatory SNPs within 10,000 flanking base pairs of the Ifnb 
genetic sequence (60, 61) and suggests a novel mechanism for IFN-β regulation, which is 
a topic of future investigation. Here, the congenic mice provided a unique tool to 
segregate IFN-β initiation from feed-forward amplification, and radiation chimeras 
demonstrated that the Bbaa1 arthritis-initiating lineage is radiation-sensitive in the joint. 
This finding is in contrast to our previous publication on the Bbaa2 QTL, in which the 
hypomorphic allele of Gusb drives arthritis through the radiation-resistant resident joint 
population (22). Thus, our forward genetic approach has identified two distinct QTLs that 
regulate Lyme arthritis through independent mechanisms and responsible initiating 
tissues.  
In the case of Bbaa1, the discrimination among cell types along with refined 
congenic lines was critical to understanding the mechanism of arthritis development. An 
unbiased RNA-seq on resident (CD45-) joint cells led to the third major finding that 
Bbaa1-directed production of IFN-β causes myostatin upregulation. This was surprising 
given that myostatin is widely appreciated for its role as a negative regulator of skeletal 
muscle growth and regeneration (62), and intensely investigated for its positive impact on 
food production in the animal agriculture industry. Nevertheless, we were able to utilize 
newly developed reagents in the field of muscle development to inhibit myostatin protein 
activity in vivo and discovered that myostatin is a direct mediator of Bbaa1 Lyme arthritis 
development. Strikingly, myostatin was recently found to be a mediator of a distinct 
inflammatory arthritis using the TNF-α overexpression model of RA in mice, and found 
to be expressed by synovial fibroblasts from patients with RA (45).  
Although we do not completely understand the mechanism of myostatin-mediated 
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inflammation in Lyme arthritis development, myostatin promotes RA in TNF-α 
overexpressing mice by activating osteoclast differentiation (45). Although bone 
pathologies have not been widely investigated in Lyme arthritis patients or mice, Tang et 
al. recently identified B. burgdorferi infection in mice bone, but implicated osteoblast 
inhibition in bone destruction (63). Interestingly, Hodzic et al. have also identified B. 
burgdorferi in quadriceps muscle (64, 65), suggesting that a more global dysregulation of 
bone and muscle homeostasis could be involved in Lyme arthritis development than 
previously appreciated. Future studies are needed to investigate the role of myostatin in 
osteoclasts and other tissues of the joint. 
Herein, we modeled the power of forward genetics in allowing the impact of 
genetics on pathogenic responses to be directly assessed, and this is the second report of 
forward genetic identification of novel genes associated with Lyme arthritis development 
(22). Identifying IFN-β as the pathologic type I IFN in Bbaa1 Lyme arthritis parallels the 
finding that IFN-β is more pathologic than IFN-α in RA patients (66), and underscores 
the need to assess IFN-α/β ratios in serum from Lyme patients as an indicator of disease 
severity. The more selective blockade of a single IFN may also be more amendable to 
clinical outcomes where the entire type I IFN response has not been ablated, and 
myostatin may be a tantalizing target for therapeutic intervention that is outside of the 
conventional inflammatory host defense (67). Together, these findings provide an 
exciting new platform to help patients with Lyme disease. 
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Figure 3.1. mAb blocking of IFN-β suppresses Bbaa1-Lyme arthritis to the same extent 
as IFNAR1-blockade. B6.C3-Bbaa1 mice were infected with 2 x 104 B. burgdorferi and 
treated with anti-IFNAR1 (MAR1-5A3), anti-IFN-α (TIF-3C5) or anti-IFN-β (HDβ-4A7) 
as described in Materials and Methods (n = 5 to 6 mice per group). (A) Arthritis was 
assessed 4 wk post infection, and shown for change in ankle measurement and overall 
lesion scores. (B) Host defense was assessed by anti-B. burgdorferi IgG in the serum and 
B. burgdorferi 16S rRNA transcripts in the joint. Statistical significance for ankle 
swelling, serum IgG, and bacterial numbers in the joint were determined by 1-way 
ANOVA followed by Dunnett’s multiple comparison test versus isotype, and Mann-









































Figure 3.2. IFN-β drives the type I IFN profile in B6.C3-Bbaa1 BMDMs in response to 
B. burgdorferi. (A) qRT-PCR analysis of transcripts after 6 hr stimulation with live B. 
burgdorferi (10:1 MOI) and treatment with anti-IFNAR1, anti-IFN-α, or anti-IFN-β 
(10µg/ml each). Transcript levels for Oasl2, Gbp2, Cxcl10, Tyki, Iigp, and Tnfa were 
normalized to β-actin. Data are pooled from two experiments conducted on separate days 
(n = 4 per group). Significance determined by 1-way ANOVA followed by Dunnett’s 
multiple comparison test versus media. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. (B) Flow cytometric analysis of Stat-1 phosphorylation after 15 hr stimulation 
with B. burgdorferi and treatment with blocking antibodies. Data are representative of 




















































































































Figure 3.3. Reciprocal radiation chimeras between B6 and B6.C3-Bbaa1 mice. (A) 
Experimental design: following a lethal dose of irradiation, B6 mice were reconstituted 
with B6.C3-Bbaa1 splenocytes (Bbaa1→B6) and B6.C3-Bbaa1 mice were reconstituted 
with B6 splenocytes (B6→Bbaa1). Autologous transplants (B6→B6 and Bbaa1→Bbaa1) 
were also generated for impact of myeloablative radiation. Arrows indicate direction of 
transplantation from donor to recipient. (B) Bbaa1 influences arthritis severity through 
the radiosensitive hematopoietic lineage. Notably, Bbaa1→B6 mice developed the full 
Lyme arthritis phenotype while B6→Bbaa1 mice were resistant. Arthritis measurements 
were taken 4 wk post infection with B. burgdorferi (n = 8 to 19 mice per group). 
Statistical significance was assessed between mice of the same recipient genotype by 
Student t test for ankle swelling and Mann-Whitney U test for overall lesion. *p < 0.05. 
(C) Model depicting the cellular “pass off” between radiosensitive myeloid (CD45+) cells 
that initiate IFN-β in response to B. burgdorferi and radioresistant resident (CD45-) cells 
that respond to IFN-β and drive arthritis development.  
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Figure 3.4. Physical boundaries of Bbaa1 congenic intervals (left) and Lyme arthritis 
(right) reveal that mice with C3H-derived genes spanning the type I IFN locus have 
increased arthritis severity compared to B6 mice. Parentheses indicate the exact interval 
of each congenic line, and rows represent the genetic composition across Chr4, with 
C3H-derived regions shaded black and B6-derived regions in white. Arthritis shown for 
ankle swelling measured 4 wk after B. burgdorferi infection (n = 10 to 35 mice per 
group). Significance assessed by 1-way ANOVA followed by Dunnett’s multiple 
comparison test versus B6. *p < 0.05, ****p < 0.0001.  
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Figure 3.5. BMDMs reveal that Bbaa1 genes regulating the magnitude of the IFN 
response to B. burgdorferi are retained in the genetic intervals of ISRCL3 and ISRCL4 
mice. qRT-PCR analysis of transcripts in BMDMs from B6, B6.C3-Bbaa1, ISRCL3, 
ICRCL4, and C3H mice stimulated with live B. burgdorferi for 6 hr (n = 3 to 4 per 
group). Transcript levels for Ifnb, Gbp2, Cxcl10, Iigp, and Tyki were normalized to β-
actin. Significant difference from B6 mice is shown and was determined by Student t test. 







































































































































































Figure 3.6. RNA-seq identification of myostatin (Mstn) as the strongest candidate for 
Bbaa1-directed Lyme arthritis development. (A) Volcano plot depicts log2 fold change 
(x-axis) and –log10 adjusted p-value (y-axis) of genes identified by ISRCL4 vs. B6 RNA-
seq comparison. Single genes are plotted as dots, with those achieving significance (p-adj 
<0.05) colored black (n = 5 per group). Red and blue dashed lines mark 1.5-fold increase 
in the congenic or B6, respectively. Circled genes also had >1.5-fold change and p-adj 
<0.05 in the ISRCL3 vs. B6 RNA-seq comparison. (B) qRT-PCR confirmation of Mstn 
expression in CD45- cells isolated from B6, ISRCL4, and ISRCL3 mice that were 
infected with B. burgdorferi for 22 days (n = 5 to 6 per group). Mstn transcripts were 
normalized to β-actin and fold change relative to uninfected levels were calculated for 
each strain. Significance assessed by 1-way ANOVA followed by Dunnett’s multiple 
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Figure 3.7. IFN-β and B. burgdorferi are both required for the expression of myostatin by 
CD45- joint cells during infection and ex vivo. (A.) In vivo mAb blocking of IFN-β 
(600µg total) prevents transcriptional upregulation of Mstn in CD45- joint cells from 
ISRCL4 and ISRCL3 mice 22 days post infection with B. burgdorferi (n = 3 to 4 per 
group). Mstn transcripts were normalized to β-actin and fold change relative to isotype 
control was calculated for each strain. Significance determined by unpaired Student t test.  
*p < 0.05, **p < 0.01. (B.) Ex vivo administration of exogenous IFN-β (100U/ml) in 
combination with B. burgdorferi (10:1 MOI) for 3 hr caused transcriptional upregulation 
of Mstn in CD45- cells isolated from a naïve B6 mouse joint. Transcripts were 
normalized to β-actin and fold change was calculated relative to media control. Results 
are pooled data from two experiments using CD45- cells from 8 or more mice done on 
separate days (n = 5 wells per group). Significance determined by 1-way ANOVA 
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Figure 3.8. Myostatin inhibition suppresses the development of Lyme arthritis in Bbaa1 
congenic mice. ISRCL4 mice were infected with 2 x 104 B. burgdorferi and treated with 
a myostatin inhibitor as described in Materials and Methods (n = 3 to 4 mice per group). 
Arthritis was assessed 4 wk post infection, and shown for change in ankle measurement. 


























Figure 3.S1. Isotype control does not impact the expression of IFN-inducible genes in 
BMDMs. qRT-PCR analysis of transcripts 6 hr post stimulation with live B. burgdorferi 
(10:1 MOI) and treatment with anti-IFN-β or isotype control (10µg/ml each). Transcript 
levels for Tyki, Oasl2, Gbp2, and Iigp were normalized to β-actin. Significance was 














































































Figure 3.S2. Confirmation of anti-IFN-α functionality. Flow cytometric analysis of Stat1 
phosphorylation in BMDMs 15 min post stimulation with exogenous murine IFN-αA 
alone (3.3ng/ml) or in combination with anti-IFN-α or anti-IFNAR1 (10µg/ml each). 
Exogenous IFN-αA potently induced Stat1 phosphorylation (black line), isotype control 
had no effect on induction (dashed line), and anti-IFN-α or anti-IFNAR1 completely 




 Figure 3.S3. Radiation chimera reconstitution efficiency and impact on host defense. (A) 
The percentages of donor-derived and recipient-derived cells in mice that were lethally 
irradiated and reconstituted with splenocytes, 25 days post transplant. Myeloid 
compartments were sufficiently reconstituted by donor-derived cells (~80%) prior to 
infection. B and T cells were about 50% donor-derived, but are dispensable for Lyme 
arthritis development. Statistical significance assessed by Student t test. ****p < 0.0001. 
(B) Reconstitution of irradiated mice was adequate for host defense, as measured by anti-












































Figure 3.S4. Confirmation of cell viability in CD45- cells isolated from naïve B6 mouse 
joint and stimulated ex vivo. Administration of exogenous IFN-β (100U/ml) for 3 hr 
caused transcriptional upregulation of IFN-inducible genes (Tyki, Cxcl10, and Gbp2), and 
addition of B. burgdorferi (10:1 MOI) for 3 hr induced expression of Tnfa. Transcripts 
were normalized to β-actin. Results are pooled data from two experiments using CD45- 
cells from 8 or more mice done on separate days (n = 5 wells per group). Significance 
determined by 1-way ANOVA followed by Dunnett’s multiple comparison test versus 













































































































































Figure 3.S5. Volcano plot of genes identified in ISRCL3 vs. B6 RNA-seq comparisons. 
Plot depicts log2 fold change (x-axis) and –log10 adjusted p-value (y-axis). Single genes 
are plotted as dots, with those achieving significance (p-adj <0.05) colored black (n = 5 
per group). Red and blue dashed lines mark 1.5-fold increase in the congenic or B6, 
respectively. Circled genes also had >1.5-fold change and p-adj <0.05 in the ISRCL3 vs. 
B6 RNA-seq comparison. Myostatin (Mstn) was again identified as the most highly 
induced gene in ISRCL3 mice.  
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Harnessing the power of forward genetics, B6.C3-Bbaa1 mice allowed for 
mechanistic interrogation of the Bbaa1 QTL, independent from the other 5 QTL 
regulating Lyme arthritis severity on the C3H background (1, 2). The finding that B6.C3-
Bbaa1 mice have increased Lyme arthritis compared to B6 mice, but intermediate to C3H 
mice, confirmed that Bbaa1 is one of multiple Lyme arthritis regulators, and is consistent 
with our previous identification of another major regulator, Gusb in the Bbaa2 QTL (3). 
Complete suppression of Lyme arthritis in B6.C3-Bbaa1 mice by anti-IFNAR1 mAb 
blockade further revealed that their intermediate phenotype is entirely due to pathologic 
type I IFN production, which is complementary to our previous publications showing that 
type I IFN drives ~50% of the arthritis phenotype in C3H mice (4, 5). Refined, interval 
specific recombinant congenic lines (ISRCL1-4) further supported that Lyme arthritis 
severity is uniquely linked to the C3H allele for the type I IFN locus, and precise 
treatment of B6.C3-Bbaa1 mice with anti-IFN-α or anti-IFN-β mAbs established that 
IFN-β is the sole arthritis-driving factor. Thus, our Bbaa1 congenic mouse model has 
provided a unique opportunity to explore all aspects of IFN-β dysregulation on a highly 
genetically similar B6 background.  
Because Bbaa1 intrinsically controls IFN-β production, reciprocal radiation 
chimeras between B6.C3-Bbaa1 and B6 mice allowed in vivo identification of the 
cellular source of pathologic IFN-β, independent from feed-forward amplification. 
Previously, reciprocal radiation chimeras between C3H and C3H-IFNAR1-/- mice 
revealed that both radiation-sensitive and radiation-resistant cells in the joint contribute to 
the proarthritic type I IFN response (5). Now, B6 and B6.C3-Bbaa1 mice specified that 
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radiation-sensitive (likely myeloid) cells initiate IFN-β, and radiation-resistant cells 
responding to IFN-β manifest arthritis in the joint. Identifying this segregation of roles 
among cell types in the joint milieu, coupled with the generation of refined congenic lines 
(in which the original 85 Mbp C3-Bbaa1 locus was reduced to 10 and 5 Mbp in ISRCL3 
and ISRCL4 mice, respectively), prompted us to design cell-appropriate RNA-seq 
experiments to better understand: the mechanism of arthritis development (wherein 
myostatin was identified, Chapter 3), and the mechanism of IFN-β dysregulation 
(wherein expressed Bbaa1 candidates were identified, Appendix). In summary, our utility 
of unbiased genetic tools throughout this dissertation has allowed us to distinguish key 
players in Bbaa1-directed Lyme arthritis development from start to finish.  
 
Possible Mechanism of IFN-β Dysregulation 
It is reasonable to suggest that another gene in the 5-10 Mbp Bbaa1 interval 
regulates IFN-β expression because Ifnb is identical between B6 and C3H mice 
(including the well-characterized enhanceosome (6)), and there are only two noncoding 
SNPs (positioned at 3,000 bps upstream and 1,000 bps downstream) within 10,000 
flanking base pairs of the coding sequence (7, 8), neither of which has any connection to 
IFN-β regulation in the literature. Interestingly, this observation is consistent with the fact 
that genome-wide association studies (GWASs) and other genetic analyses for systemic 
lupus erythematosus (a prototypic autoimmune disease with a type I IFN signature) have 
never identified susceptibility polymorphisms in the actual IFN-α/β genetic sequences, 
but have identified many genes involved in the IFN signaling pathway (9–13). Although 
there is not another gene in the Bbaa1 interval that has been linked to IFN signaling 
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before, novel mechanisms of IFN-β regulation are continually being discovered (14). 
Thus, a Bbaa1 gene that is (1) expressed in the same (myeloid) cell type that initiates 
Ifnb, (2) expressed during or prior to Ifnb expression, and (3) polymorphic between B6 
and C3H sequences (to explain subsequently differential Ifnb expression) may be 
responsible for this novel function.  
Based on the aforementioned criteria, an unbiased RNA-seq experiment was 
performed, and a list of Bbaa1 candidates was generated to serve as a starting point for 
future studies defining this novel mechanism (Appendix). Intriguingly, the list 
encompasses enzymes (which, as a broad category, are often identified in GWAS studies 
and majorly impact cell signaling pathways (15)), lincRNAs (which play important gene 
regulatory roles (16, 17), especially in myeloid cells (18–26), with lincRNA-Cox2 
exemplifying a transcriptional repressor of type I IFN signaling in resting macrophages 
(26)), and unannotated genes (which is consistent with this being a novel gene function). 
In summary, the progression of this dissertation has led to a manageable number of 
exciting Bbaa1 candidates to be tested in future studies.  
  
Investigations in Bbaa1 Mice Will Transcend Lyme Disease 
Understanding the genetic mechanism of Bbaa1-directed IFN-β dysregulation will 
be highly impactful because a number of human diseases are associated with a pathologic 
type I IFN signature (27–31), and Bbaa1 mice provide a natural model for this genetic 
phenomenon. Although there has not yet been a GWAS for Lyme disease, GWASs for 
many autoimmune diseases with a type I IFN signature (including systemic lupus 
erythematosus, type I diabetes, rheumatoid arthritis, Sjögren’s syndrome, and systemic 
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sclerosis) have identified common susceptibility genes (notably Irf5 and Ifih1) involved 
in type I IFN signaling (15, 32). This highlights that shared genetic polymorphisms 
(especially those impacting the type I IFN pathway) can manifest as different diseases, 
and underscores the widespread importance of characterizing the novel Bbaa1 
susceptibility gene.  
Additional similarities between our murine model of Lyme arthritis and several 
human autoimmune diseases further illuminate the power of our Bbaa1 mouse tool. 
Specifically, type I diabetes patients display a transient but robust type I IFN profile that 
precedes active disease (31), similar to the kinetics we observe during Lyme arthritis 
development in C3H and B6.C3-Bbaa1 mice (Crandall et al. (33) and Chapter 2). IFN-β 
also seems to be more pathologic than IFN-α in rheumatoid arthritis patients (34), similar 
to our finding that IFN-β is the proarthritogenic factor in B6.C3-Bbaa1 mice (Chapter 3). 
And, patients with idiopathic inflammatory myopathies display a type I IFN signature 
(35–38) and share susceptibility genes with other autoimmune disorders (39, 40), 
suggesting that myostatin upregulation in B6.C3-Bbaa1 mice (Chapter 3) occurs via a 
shared pathological pathway downstream of a common type I IFN trigger. In conclusion, 
future studies in Bbaa1 mice will likely contribute to a global understanding of 
pathological processes shared among many human diseases. 
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RNA-SEQ IDENTIFICATION OF BBAA1 CANDIDATES THAT  
ARE EXPRESSED IN BONE MARROW-DERIVED  
MACROPHAGES FROM B6, ISRCL3,  








Table A.1. RNA-seq identification of Bbaa1 candidates that are expressed in bone 
marrow-derived macrophages from B6, ISRCL3, and ISRCL4 mice. An unbiased RNA-
seq experiment was conducted to identify candidate Bbaa1 genes regulating IFN-β within 
the ISRCL3 interval (Chr4: 83.7 – 93.46, green line) and ISRCL4 interval (Chr4: 88.3 – 
93.46, yellow line) based on transcriptional activity at or prior to the peak of Ifnb 
expression. Because bone marrow-derived macrophages are an appropriate model for 
myeloid cells in joint tissue, macrophages from B6, ISRCL3, and ISRCL4 mice were 
cultured as described previously (Chapters 2 and 3, Materials and Methods) and 
stimulated with live B. burgdorferi for 0, 3, or 6 hr (n = 3 to 4 mice per genotype). RNA-
seq libraries were prepared using a Ribo-Zero rRNA removal kit in order to retain the 
maximal number of both coding and noncoding RNA transcripts, and sequenced as 
described previously (Chapter 3, Materials and Methods). Shown is a list of candidate 
genes arranged in ascending order along Chr4. Genes with SNPs between B6 and C3H 
sequences are noted, and will be the subject of future investigations determining the 
consequence of structural changes on IFN-β regulation.  
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